# Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

> **NCT06801002** · PHASE1 · RECRUITING · sponsor: **Jabez Bioscience, Inc** · enrollment: 25 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** JBZ-001

## Key facts

- **NCT ID:** NCT06801002
- **Lead sponsor:** Jabez Bioscience, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-17
- **Primary completion:** 2027-02-15
- **Final completion:** 2028-02-15
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06801002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06801002, "Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06801002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*